0 CHECKOUT

Rhinovirus Infection - Pipeline Review, H2 2015

  • ID: 3412703
  • August 2015
  • 55 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AIMM Therapeutics B.V.
  • Biological Mimetics, Inc.
  • Boehringer Ingelheim GmbH
  • Johnson & Johnson
  • Myelo Therapeutics GmbH
  • Novartis AG
  • MORE

The report ‘Rhinovirus Infection - Pipeline Review, H2 2015’, provides an overview of the Rhinovirus Infection’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rhinovirus Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rhinovirus Infection and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AIMM Therapeutics B.V.
  • Biological Mimetics, Inc.
  • Boehringer Ingelheim GmbH
  • Johnson & Johnson
  • Myelo Therapeutics GmbH
  • Novartis AG
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Rhinovirus Infection Overview

Therapeutics Development

Pipeline Products for Rhinovirus Infection - Overview

Pipeline Products for Rhinovirus Infection - Comparative Analysis

Rhinovirus Infection - Therapeutics under Development by Companies

Rhinovirus Infection - Therapeutics under Investigation by Universities/Institutes

Rhinovirus Infection - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Rhinovirus Infection - Products under Development by Companies

Rhinovirus Infection - Products under Investigation by Universities/Institutes

Rhinovirus Infection - Companies Involved in Therapeutics Development

AIMM Therapeutics B.V.

Biological Mimetics, Inc.

Biota Pharmaceuticals, Inc.

Boehringer Ingelheim GmbH

Johnson & Johnson

Myelo Therapeutics GmbH

Novartis AG

Theraclone Sciences, Inc.

Rhinovirus Infection - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

KR-22809 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody for Asthma, COPD and Rhinovirus Infections - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody for Human Rhinovirus Infections - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Myelo-001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

OBR-5340 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PL-402 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Recombinant Protein for Rhinovirus Infection - Drug Profile

Product Description

Mechanism of Action

R&D Progress

rhinovirus [serotype 39] vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Inhibit PI4KIII beta for Rhinovirus Infection - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Rhinovirus Infection - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Rhinovirus Infections - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit RNA Polymerase for Rhinovirus and Picornaviridae Infections - Drug Profile

Product Description

Mechanism of Action

R&D Progress

vapendavir - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Rhinovirus Infection - Recent Pipeline Updates

Rhinovirus Infection - Dormant Projects

Rhinovirus Infection - Product Development Milestones

Featured News & Press Releases

Mar 03, 2015: Biota Commences Dosing in Vapendavir SPIRITUS Phase 2b Trial

Mar 28, 2012: Biota Announces Positive Phase IIb Data In Asthma Patients With Human Rhinovirus Infection

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Rhinovirus Infection, H2 2015

Number of Products under Development for Rhinovirus Infection - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015

Rhinovirus Infection - Pipeline by AIMM Therapeutics B.V., H2 2015

Rhinovirus Infection - Pipeline by Biological Mimetics, Inc., H2 2015

Rhinovirus Infection - Pipeline by Biota Pharmaceuticals, Inc., H2 2015

Rhinovirus Infection - Pipeline by Boehringer Ingelheim GmbH, H2 2015

Rhinovirus Infection - Pipeline by Johnson & Johnson, H2 2015

Rhinovirus Infection - Pipeline by Myelo Therapeutics GmbH, H2 2015

Rhinovirus Infection - Pipeline by Novartis AG, H2 2015

Rhinovirus Infection - Pipeline by Theraclone Sciences, Inc., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Rhinovirus Infection Therapeutics - Recent Pipeline Updates, H2 2015

Rhinovirus Infection - Dormant Projects, H2 2015

List of Figures

Number of Products under Development for Rhinovirus Infection, H2 2015

Number of Products under Development for Rhinovirus Infection - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

AIMM Therapeutics B.V.
Biological Mimetics, Inc.
Biota Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
Johnson & Johnson
Myelo Therapeutics GmbH
Novartis AG
Theraclone Sciences, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.